48.25MMarket Cap-806P/E (TTM)
2.061High1.950Low112.74KVolume2.060Open2.060Pre Close225.55KTurnover0.80%Turnover RatioLossP/E (Static)24.61MShares5.70052wk High0.61P/B27.72MFloat Cap1.21052wk Low--Dividend TTM14.14MShs Float65.250Historical High--Div YieldTTM5.39%Amplitude1.210Historical Low2.000Avg Price1Lot Size
Aadi Biosciences Stock Forum
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval. The company will now focus on its FYARRO® commercial business for PEComa and conduct a strategic review. To extend cash runway into at least 2H 2026, Aadi will:
Adjust ongoing Phase 2 trials
Reduce R&D headcount by 80%
Pause...
NEWS
Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting
Aadi Bioscience presented new nonclinical data at the ASCO Annual Meeting showing that nab-sirolimus achieved higher intratumoral drug concentrations, stronger mTOR target inhibition, and greater antitumor activity compared to IV and oral mTOR inhibitors in a xenograft model. These findings suppo...
$Envoy Medical (COCH.US)$ $CXApp (CXAI.US)$ $Aadi Biosciences (AADI.US)$ $CURO Group (CURO.US)$ $BigBear.ai Holdings (BBAI.US)$ $Fisker (FSR.US)$ $Ainos (AIMD.US)$
📊⚡️📊
• $Red Robin (RRGB.US)$ +13.8% (In reaction to earnings)
• $PMV Pharmaceuticals (PMVP.US)$ +11.2% (ASCO-related announcement)
• $Sumo Logic (SUMO.US)$ +10.8% (In reaction to earnings)
• $Adicet Bio (ACET.US)$ +9.6% (ASCO-related announcement)
• $Dell Technologies (DELL.US)$ +9.6% (In reaction to earnings)
• $ImmunoGen (IMGN.US)$ +8.7% (ASCO-related announcement)
• $Ulta Beauty (ULTA.US)$ +7.9% (In reaction to earnings)
• $Zymergen (ZY.US)$ +7.8% (to...
No comment yet